Wendy Patricia Flynn

LYRtech, Inc. develops and manufactures advanced digital signal processing solutions for companies worldwide. It provides vital technologies to network and wireless communications, audio & video processing and other electronic systems in all fields of technology. The firm offers a full range of DSP-FPGA development platforms and also designs prototyping and manufacturing of electronic products. It markets a line of products and software in the fields of digital signal processing based platforms and electro optics. The company was founded by Louis N. Bélanger and Louis Chouinard in 1983 and is headquartered in Quebec City, Canada.

Bionpharma, Inc. provides various specialty pharmaceuticals. It offers Rx generic ANDA and OTC products. The company was founded on Noveber 1, 2014 and is headquartered in Princeton, NJ.

Centraide of Greater Montreal supports community agencies in the neighbourhoods. It has four areas of action: supporting youth, providing basic needs, helping the socially isolated and bringing communities together. The company was founded in 1966 and is headquartered in Montr?al, Canada.

The Canadian Generic Pharmaceutical Association provides generic prescription medicines and active pharmaceutical ingredients. The company was founded in 1984 and is headquartered in Toronto, Canada.

10379085 Canada, Inc. is an investment holding Canadian company founded in 2017. The private company is based in Montréal, Canada.

Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.